4.7 Article

Novel Combinations of Vancomycin plus Ceftaroline or Oxacillin against Methicillin-Resistant Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA

期刊

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 57, 期 5, 页码 2376-2379

出版社

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.02354-12

关键词

-

资金

  1. Astellas
  2. Cubist
  3. Forest
  4. Pfizer
  5. Novartis
  6. Rib-X
  7. NIH [R21A1092055-01, GM073898]
  8. Ortho-McNeil Pharmaceuticals
  9. Cubist Pharmaceuticals

向作者/读者索取更多资源

We demonstrated a significant inverse correlation between vancomycin and beta-lactam susceptibilities in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA (hVISA) isolates. Using time-kill assays, vancomycin plus oxacillin or ceftaroline was synergistic against 3 of 5 VISA and 1 of 5 hVISA isolates or 5 of 5 VISA and 4 of 5 hVISA isolates, respectively. Beta-lactam exposure reduced overall vancomycin-Bodipy (dipyrromethene boron difluoride [4,4-difluoro-4-bora-3a, 4a-diaza-s-indacene] fluorescent dye) binding but may have improved vancomycin-cell wall interactions to improve vancomycin activity. Further research is warranted to elucidate the mechanism behind vancomycin and beta-lactam synergy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据